
GM profit hurt by over $1B in tariffs — and shares tumble as impact expected to worsen
The largest US automaker by sales said it expects the tariff impact to worsen in the third quarter and stuck to a previous estimate that trade headwinds threaten to hit the bottom line by $4 billion to $5 billion.
GM said it could take steps to mitigate at least 30% of that impact.
Shares fell about 6% in early trading.
3 GM's revenue in the quarter fell nearly 2% to about $47 billion from a year ago. Its quarterly adjusted earnings per share fell to $2.53 compared with $3.06 a year earlier.
Bloomberg via Getty Images
The automaker's revenue in the quarter ended June 30 fell nearly 2% to about $47 billion from a year ago. Its quarterly adjusted earnings per share fell to $2.53 compared with $3.06 a year earlier.
Analysts on average expected adjusted profit of $2.44 per share, according to data compiled by LSEG.
Its adjusted earnings before interest and taxes fell 32% to $3 billion.
GM was among corporations that revised annual guidance due to the impact from President Trump's tariffs, lowering it to an annual adjusted core profit of between $10 billion and $12.5 billion.
The company on Tuesday stood by that forecast.
Beyond tariffs, GM's underlying business in the quarter was solid. Sales in the US market – its main profit center – rose 7%, while the company continued to command strong pricing on its pickup trucks and SUVs.
GM swung back to a small profit in China, after losing money there a year earlier.
Analysts said GM may need to cut investment in future projects or find other ways to trim spending to offset the effect of tariffs.
Jeep-maker Stellantis on Monday warned that tariffs would significantly affect results in the second half of 2025, and said tariffs cost it about 300 million euros in the first half of the year.
Shares of rival Ford Motor, and US-traded shares of Stellantis fell about 1% Tuesday morning.
3 Analysts said GM may need to cut investment in future projects or find other ways to trim spending to offset the effect of tariffs. CEO Mary Barra, above.
AP
The automaker took several steps in recent months to bolster its combustion-engine operations through increased investment in its US factory base, calling into question its goal of ending the production of gas-powered cars and trucks by 2035.
'Despite slower EV industry growth, we believe the long-term future is profitable electric vehicle production, and this continues to be our North Star,' GM CEO Mary Barra told analysts Tuesday.
GM announced in June that it would invest $4 billion at three facilities in Michigan, Kansas, and Tennessee, including a plan to move production of the Cadillac Escalade and increase output of its two big pickup trucks. It added production of its previously Mexico-produced Chevy Blazer to the Tennessee plant.
The automaker imports about half of the vehicles it sells in the US, mainly from Mexico and South Korea.
Crosstown rival Ford produces about 80% of its US-sold vehicles domestically. Ford is expected to report second-quarter results next week.
3 GM imports about half of the vehicles it sells in the US, mainly from Mexico and South Korea.
REUTERS
Car companies are increasingly shifting their focus to bolstering the core lineup of gas trucks and SUVs, as the growth rate of EV sales has slowed.
Demand for battery-powered models already has slowed after rapid growth earlier this decade.
The trend is intensified by the pending disappearance of government support for the battery-powered models.
Sweeping tax and budget legislation approved by Congress will eliminate $7,500 tax credits for buying or leasing new electric vehicles and a $4,000 used-EV credit at the end of September.
Trump also signed tax and budget legislation that eliminates fines for failures to meet fuel economy rules, a move that makes it easier to build more gas-powered vehicles.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
21 minutes ago
- Yahoo
Mounjaro and Zepbound fuel strong Q2 growth for Eli Lilly
Eli Lilly reported growth of 172% and 68% for weight loss drug Zepbound and type 2 diabetes (T2D) treatment Mounjaro, respectively, in Q2 2025, though ceded early advantage to Novo Nordisk in the oral glucagon-like receptor agonist (GLP-1RA) arena. Eli Lilly's two tirzepatide drugs, rival to Novo Nordisk's semaglutide, brought in a combined $8.57bn in the quarter, compared to $4.33bn in Q2 2024. Mounjaro led the growth with approximately $5.2bn, while Zepbound generated around $3.4bn. Mounjaro and Zepbound helped drive the US drugmaker's total Q2 revenue to $15.56bn, up 38% from the same period last year. In a conference call, Eli Lilly CEO David Ricks acknowledged the role the two brands played in the company's revenue, highlighting their strong sales and the company's optimism for high-growth ceilings. Eli Lilly now expects full-year revenue between $60bn and $62bn, up from its previous range of $58bn to $61bn. The raise contrasted with rival Novo Nordisk, which reduced its 2025 outlook last week based on headwinds in the GLP-1RA space. However, shares in Lilly dropped 12% after market open to $656.19 following disappointing data published on the same day for oral weight loss candidate orforglipron. The GLP-1RA arena is set for a major juncture amid the potential approval of more patient-friendly oral versions. Both Novo Nordisk and Eli Lilly are developing candidates in this market and vying for an early lead. Results at orforglipron's highest dose, taken once a day, showed a 12.4% (27.3lb) weight loss at 72 weeks. Novo Nordisk's candidate – which was submitted to the US Food and Drug Administration (FDA) for approval in May 2025 – led to a 13.6% average weight loss. However, Lilly has a strong injectable GLP-1RA foundation on which to build. The 68% growth for Mounjaro, sold in the UK and Europe under the same brand name for both diabetes and weight loss, far surpassed that for Novo Nordisk's Ozempic, which only grew 15% in Q2 compared to the same period last year. Wegovy's global sales fared more favourably, growing 75% in Q2. Wegovy, which has been on the market longer than Zepbound, generated just over $16bn more than Lilly's asset. Analysis by GlobalData still forecasts a higher sales ceiling for tirzepatide by 2031 due to the drug's improved efficacy over semaglutide. Pricing discussions with Trump Eli Lilly is part of a wider pharmaceutical industry battling pricing reforms instigated by US President Donald Trump. The administration is seeking to install a most favoured nation pricing model that would match the costs of certain prescription drugs in the country to the lower prices offered in other developed nations. Executives were coy when asked about potential discussions with Trump, with CEO Ricks saying that 'long term it makes sense to rebalance [pricing].' 'We support the administration's position that medical research costs need to be shared more equitably across developed countries,' Ricks commented. Ricks went on to explain that defects in the US pharma market shift costs to patients and increase red tape. In Pfizer's Q2 earnings call, CEO Albert Bourla said it is in 'very active discussions' around drug pricing. He also confirmed that he personally discussed the matter with Trump, following letters to 17 drugmakers – including Eli Lilly – last week calling for price cuts. "Mounjaro and Zepbound fuel strong Q2 growth for Eli Lilly" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Sign in to access your portfolio
Yahoo
21 minutes ago
- Yahoo
GM to import EV batteries from CATL, WSJ reports
(Reuters) -General Motors will import electric vehicle batteries from Chinese battery giant CATL, The Wall Street Journal reported on Thursday. The arrangement is a stopgap for GM as it works to manufacture its own lower-cost batteries made with lithium iron phosphate (LFP) chemistry, the report added. Global automakers are facing stiff competition from Chinese EV makers and a trade war impacting imports of crucial parts, including rare earth materials, which has pushed production costs higher. GM did not immediately respond to a Reuters request for a comment. Crosstown rival Ford is also making battery cells using tech from CATL to help reduce costs on EV batteries. Reuters last year reported that GM was in talks to buy EV batteries that would use technology from CATL.
Yahoo
21 minutes ago
- Yahoo
Corn Popping Higher at Midday, Helped by Better than Expected Export Business
Corn futures are getting some buying on Thursday, after December held the $4 mark on Wednesday. Contracts are up 5 to 6 ¼ cents at midday. The CmdtyView national average Cash Corn price is us 5 3/4 cents at $3.68 1/4. USDA reported two separate private export sales of 106,680 MT to Mexico and 105,000 MT to Guatemala, both for 2025/26 shipment. More News from Barchart Coffee Prices Settle Lower on Tariff Woes Tariff Turmoil Weighs on Coffee Prices The Bullish Cattle Stampede Rumbles On. Here's What to Watch Next After Record Cattle Highs. Stop Missing Market Moves: Get the FREE Barchart Brief – your midday dose of stock movers, trending sectors, and actionable trade ideas, delivered right to your inbox. Sign Up Now! Export Sales data showed 170,428 MT in old crop corn sales, the second lowest for the MY, and below estimates calling for between 200,000 and 400,000 MT during the week of July 31. New crop business blew past the expected 1.3-2.5 MMT, at 3.16 MMT in total. That takes the total sales for 2025/26 to 11.777 MMT, the second highest for the current week on record behind 2021/22 (when China was an active buyer). Brazil exported a total of 2.434 MMT of corn during July, which was a drop of 31.51% from last year's total but well above the June total. A slower second crop harvest and soybeans still taking up a large chunk of the vessel lineup were a factor. Sep 25 Corn is at $3.85 3/4, up 6 cents, Nearby Cash is at $3.68 1/4, up 5 3/4 cents, Dec 25 Corn is at $4.07 1/2, up 6 1/4 cents, Mar 26 Corn is at $4.25 1/4, up 6 cents, New Crop Cash is at $3.66 3/4, up 6 cents, On the date of publication, Austin Schroeder did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Sign in to access your portfolio